Calcitonin dermal - PowderJect

Drug Profile

Calcitonin dermal - PowderJect

Alternative Names: PowderJect Calcitonin; Salmon calcitonin dermal - PowderJect

Latest Information Update: 16 Jan 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PowderJect Pharmaceuticals
  • Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Calcitonin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Postmenopausal osteoporosis

Most Recent Events

  • 16 Jan 2002 No-Development-Reported for Postmenopausal osteoporosis in United Kingdom (Transdermal)
  • 30 Aug 1999 Phase-I clinical trials for Postmenopausal osteoporosis in United Kingdom (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top